Research Paper Volume 12, Issue 11 pp 10162—10179

First-in-class candidate therapeutics that target mitochondria and effectively prevent cancer cell metastasis: mitoriboscins and TPP compounds

Figure 12. A large mito-ribosome gene signature predicts distant metastasis and tumor recurrence in ER(+) breast cancer patients, treated with Tamoxifen. A mito-ribosome signature predicts treatment failure in a sub-set of ER(+) patients undergoing Tamoxifen treatment, which resulted in distant metastasis (N=618 patients; HR=2.16; P=1.7e-05) and tumor recurrence (N=799 patients; HR=3.45; P=1.6e-08). See also Supplementary Tables 6 and 7 and . DMFS, distant metastasis free survival; RFS, relapse free survival.